Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia

D. Roger Illingworth, Anuradha Pappu, Richard E. Gregg

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Previous reports in which cholesterol homeostasis has been examined in patients with phenotypic abetalipoproteinemia have shown an increase in whole body cholesterol synthesis when measured by sterol balance techniques but normal rates of cholesterol synthesis when measured by isotopic cholesterol turnover. Recent studies have indicated that increases in cholesterol biosynthesis are paralleled by increases in the plasma concentrations of mevalonic acid and by higher rates of excretion of mevalonic acid in the urine. In the present report we have measured the 24-h urinary excretion of mevalonic acid in 7 patients with phenotypic abetalipoproteinemia and compared this to control subjects. Urinary excretion of mevalonic acid was significantly higher in the patients with abetalipoproteinemia (57.2 ± 10.2 nmol/kg body weight per day, mean ± SEM) as compared to control subjects (23.1 ± 1.5 nmol/kg per day). The magnitude of the increase in urinary mevalonic acid excretion seen in patients with abetalipoproteinemia (148%) is greater than the increase in whole body cholesterol biosynthesis assessed by sterol balance techniques (57% increase). Our results serve to further validate the usefulness of urinary mevalonate as an indicator of relative rates of cholesterol biosynthesis in humans and suggest that this measurement provides a valuable means to potentially screen for disorders associated with an oversynthesis of cholesterol.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalAtherosclerosis
Volume76
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Hypobetalipoproteinemias
Abetalipoproteinemia
Mevalonic Acid
Cholesterol
Sterols
Homeostasis
Body Weight
Urine

Keywords

  • Abetalipoproteinemia
  • Cholesterol synthesis
  • Hydroxymethylglutaryl CoA reductase
  • Mevalonic acid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia. / Roger Illingworth, D.; Pappu, Anuradha; Gregg, Richard E.

In: Atherosclerosis, Vol. 76, No. 1, 1989, p. 21-27.

Research output: Contribution to journalArticle

@article{46f990a622814e7f9b79deef6d914f65,
title = "Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia",
abstract = "Previous reports in which cholesterol homeostasis has been examined in patients with phenotypic abetalipoproteinemia have shown an increase in whole body cholesterol synthesis when measured by sterol balance techniques but normal rates of cholesterol synthesis when measured by isotopic cholesterol turnover. Recent studies have indicated that increases in cholesterol biosynthesis are paralleled by increases in the plasma concentrations of mevalonic acid and by higher rates of excretion of mevalonic acid in the urine. In the present report we have measured the 24-h urinary excretion of mevalonic acid in 7 patients with phenotypic abetalipoproteinemia and compared this to control subjects. Urinary excretion of mevalonic acid was significantly higher in the patients with abetalipoproteinemia (57.2 ± 10.2 nmol/kg body weight per day, mean ± SEM) as compared to control subjects (23.1 ± 1.5 nmol/kg per day). The magnitude of the increase in urinary mevalonic acid excretion seen in patients with abetalipoproteinemia (148{\%}) is greater than the increase in whole body cholesterol biosynthesis assessed by sterol balance techniques (57{\%} increase). Our results serve to further validate the usefulness of urinary mevalonate as an indicator of relative rates of cholesterol biosynthesis in humans and suggest that this measurement provides a valuable means to potentially screen for disorders associated with an oversynthesis of cholesterol.",
keywords = "Abetalipoproteinemia, Cholesterol synthesis, Hydroxymethylglutaryl CoA reductase, Mevalonic acid",
author = "{Roger Illingworth}, D. and Anuradha Pappu and Gregg, {Richard E.}",
year = "1989",
doi = "10.1016/0021-9150(89)90190-1",
language = "English (US)",
volume = "76",
pages = "21--27",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia

AU - Roger Illingworth, D.

AU - Pappu, Anuradha

AU - Gregg, Richard E.

PY - 1989

Y1 - 1989

N2 - Previous reports in which cholesterol homeostasis has been examined in patients with phenotypic abetalipoproteinemia have shown an increase in whole body cholesterol synthesis when measured by sterol balance techniques but normal rates of cholesterol synthesis when measured by isotopic cholesterol turnover. Recent studies have indicated that increases in cholesterol biosynthesis are paralleled by increases in the plasma concentrations of mevalonic acid and by higher rates of excretion of mevalonic acid in the urine. In the present report we have measured the 24-h urinary excretion of mevalonic acid in 7 patients with phenotypic abetalipoproteinemia and compared this to control subjects. Urinary excretion of mevalonic acid was significantly higher in the patients with abetalipoproteinemia (57.2 ± 10.2 nmol/kg body weight per day, mean ± SEM) as compared to control subjects (23.1 ± 1.5 nmol/kg per day). The magnitude of the increase in urinary mevalonic acid excretion seen in patients with abetalipoproteinemia (148%) is greater than the increase in whole body cholesterol biosynthesis assessed by sterol balance techniques (57% increase). Our results serve to further validate the usefulness of urinary mevalonate as an indicator of relative rates of cholesterol biosynthesis in humans and suggest that this measurement provides a valuable means to potentially screen for disorders associated with an oversynthesis of cholesterol.

AB - Previous reports in which cholesterol homeostasis has been examined in patients with phenotypic abetalipoproteinemia have shown an increase in whole body cholesterol synthesis when measured by sterol balance techniques but normal rates of cholesterol synthesis when measured by isotopic cholesterol turnover. Recent studies have indicated that increases in cholesterol biosynthesis are paralleled by increases in the plasma concentrations of mevalonic acid and by higher rates of excretion of mevalonic acid in the urine. In the present report we have measured the 24-h urinary excretion of mevalonic acid in 7 patients with phenotypic abetalipoproteinemia and compared this to control subjects. Urinary excretion of mevalonic acid was significantly higher in the patients with abetalipoproteinemia (57.2 ± 10.2 nmol/kg body weight per day, mean ± SEM) as compared to control subjects (23.1 ± 1.5 nmol/kg per day). The magnitude of the increase in urinary mevalonic acid excretion seen in patients with abetalipoproteinemia (148%) is greater than the increase in whole body cholesterol biosynthesis assessed by sterol balance techniques (57% increase). Our results serve to further validate the usefulness of urinary mevalonate as an indicator of relative rates of cholesterol biosynthesis in humans and suggest that this measurement provides a valuable means to potentially screen for disorders associated with an oversynthesis of cholesterol.

KW - Abetalipoproteinemia

KW - Cholesterol synthesis

KW - Hydroxymethylglutaryl CoA reductase

KW - Mevalonic acid

UR - http://www.scopus.com/inward/record.url?scp=0024538210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024538210&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(89)90190-1

DO - 10.1016/0021-9150(89)90190-1

M3 - Article

VL - 76

SP - 21

EP - 27

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -